The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion by 2030.
Liquid biopsies have emerged as a versatile diagnostic solution,especially for cases when conventional (invasive) diagnostic tests areinconclusive or when the clinical condition is related to an organ that is notamenable to biopsy access
Roots Analysis is pleased to announce the publication of its recent study,titled, “Liquid Biopsy and Other Non-InvasiveCancer Diagnostics Market(3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA,cfDNA, Exosomes and Other Biomarkers.”
The report featuresan extensive study of the current market landscape, offering an informedopinion on the likely adoption of this approach over the next decade. Itfeatures an in-depth analysis, highlighting the capabilities of variousstakeholders engaged in this domain. In addition to other elements, the studyincludes:
§ A detailed review ofthe overall landscape of the non-invasive cancer diagnostics market.
§ An analysis of thevarious partnerships pertaining to non-invasive cancer diagnostics, which havebeen established between 2016 and 2019.
§ An analysis of theinvestments made in companies engaged in the development of non-invasive cancerdiagnostics.
§ An analysis of theinitiatives of big pharma players.
§ A detailedacquisition target analysis.
§ Elaborate profiles ofthe key players engaged in this domain.
§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)
§ Type of Tumor Marker
§ ctDNA
§ cfDNA
§ CTCs
§ Exosomes
§ Others
§ Application
§ Diagnosis / EarlyDiagnosis
§ Patient Monitoring
§ Recurrence Monitoring
§ Target CancerIndication
§ Breast Cancer
§ Lung Cancer
§ Colorectal Cancer
§ Prostate Cancer
§ Bladder Cancer
§ Melanoma
§ Gastric Cancer
§ Pancreatic Cancer
§ Ovarian Cancer
§ Others
To request for sample report - https://www.rootsanalysis.com/reports/279/request-sample.html
§ End Users
§ Hospitals
§ Research Institutes
§ Others
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
Key companies covered in the report:
§ Amoy Diagnostics
§ DiaCarta
§ HaploX Biotechnology
§ NeoGenomics
§ QIAGEN
§ Swift Biosciences
§ Sysmex Inostics
§ Thermo Fisher Scientific
For more information,please click on the following link:
https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Other recentofferings
1. DNA-EncodedLibraries: Platforms and Services Market
2. AntibodyDiscovery: Services and Platforms Market (2nd Edition), 2018-2028
3. InSilico / Computer-Aided Drug Discovery Services
4. Cancer BiomarkersMarket:Focus on TMB, MSI / MMR and TILs Testing, 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter- https://twitter.com/RootsAnalysis
